ArticleThe World Allergy Organization journal2022

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps.

Diego Bagnasco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.